The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sensible-medical.com

Founded Year

2007

Stage

Unattributed VC - II | Alive

Total Raised

$27M

Last Raised

$20M | 9 yrs ago

About Sensible Medical Innovations

Sensible Medical Innovation develops a sensing and monitoring technology that provides actionable and accurate data for guiding the management and treatment of several chronic medical conditions.

Sensible Medical Innovations Headquarter Location

5a Giborei Israel St

Netanya, 42504,

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sensible Medical Innovations

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sensible Medical Innovations is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Sensible Medical Innovations Patents

Sensible Medical Innovations has filed 31 patents.

The 3 most popular patent topics include:

  • Electromagnetic radiation
  • Radiation
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/6/2020

3/22/2022

Electromagnetic radiation, Neurotrauma, Arteries of the head and neck, Microwave technology, Pidgins and creoles

Grant

Application Date

1/6/2020

Grant Date

3/22/2022

Title

Related Topics

Electromagnetic radiation, Neurotrauma, Arteries of the head and neck, Microwave technology, Pidgins and creoles

Status

Grant

Latest Sensible Medical Innovations News

Medicure Announces Termination Of ReDSTM Pro Marketing And Distribution Agreement

Aug 20, 2020

Medicure Announces Termination Of ReDSTM Pro Marketing And Distribution Agreement STRENGTHENS FOCUS ON MARKETING OF AGGRASTAT ®  AND ZYPITAMAG TM WINNIPEG, MB, Aug. Author: STRENGTHENS FOCUS ON MARKETING OF AGGRASTAT ®  AND ZYPITAMAG TM WINNIPEG, MB, Aug. 20, 2020 /PRNewswire/ - Medicure Inc. (" Medicure" or the " Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. (" Sensible") for the marketing of the ReDS TM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7.71% equity stake, on a fully diluted basis, in Sensible Medical Innovations Ltd. (" Sensible Medical"), the parent company of Sensible. Medicure will continue to support Sensible in its transition to a new marketing and distribution arrangement in order to secure its investment in Sensible Medical. The termination of the marketing and distribution agreement with Sensible followed an in-depth strategic review of its alignment with Medicure's other lines of business. "The discontinuation of marketing and distribution activities related to the ReDS Pro device in the United States market will result in Medicure strengthening its focus on its own products, AGGRASTAT ® and ZYPITAMAG TM, which provide a higher profit margin to Medicure" commented Dr. Albert D. Friesen, Medicure's Chief Executive Officer. About Medicure Inc.Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT ® (tirofiban hydrochloride) injection and ZYPITAMAG TM (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com . About SensibleSensible is a market leader in medical radar monitoring and imaging technology. ReDS™ was adapted for medical use from military 'see-through-wall' technology. The technology is well-positioned to be a difference maker in a wide range of applications and to become the next-generation lung fluid monitoring modality. www.sensible-medical.com About ReDS™ PRO SystemThe ReDS™ PRO is an accurate measurement tool to evaluate pulmonary congestion providing additional information to assist a physician in their assessment of a patient's condition. Assessment with the aid of ReDS™ technology has helped physicians at facilities across the country to better manage their patients' heart failure, with the goal of avoiding readmissions. For more information please visit  www.medicure.com/reds . To be added to Medicure's e-mail list, please visit:         http://medicure.mediaroom.com/alerts Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2019. View original content: http://www.prnewswire.com/news-releases/medicure-announces-termination-of-redstm-pro-marketing-and-distribution-agreement-301116054.html

Sensible Medical Innovations Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sensible Medical Innovations Rank

  • When was Sensible Medical Innovations founded?

    Sensible Medical Innovations was founded in 2007.

  • Where is Sensible Medical Innovations's headquarters?

    Sensible Medical Innovations's headquarters is located at 5a Giborei Israel St, Netanya.

  • What is Sensible Medical Innovations's latest funding round?

    Sensible Medical Innovations's latest funding round is Unattributed VC - II.

  • How much did Sensible Medical Innovations raise?

    Sensible Medical Innovations raised a total of $27M.

  • Who are Sensible Medical Innovations's competitors?

    Competitors of Sensible Medical Innovations include SynCardia Systems, OptiScan Biomedical, Cardiopulmonary, GluMetrics, GlySure and 16 more.

You May Also Like

O
OptiScan Biomedical

OptiScan Biomedical has developed a monitoring platform for use in hospital intensive care units (ICU) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention. The OptiScanner platform is presently focused on delivering automated bedside glucose monitoring to support clinicians' reach and maintain the right level of glucose control.

S
Solianis Monitoring

Solianis is a Swiss medical device company developing products for physiological monitoring

K
Kemeta

KemetaTMis commercializing palm-size breath analyzers for monitoring the body'ss metabolism with an initial focus on weight management.

C
Cellatope

Cellatope uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases

C
Critisense

technology for real-time monitoring of the metabolic state of the patient and as a endpoint of resuscitationn nCritisense's first generation product - the "CritiView" is an patient monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, reflecting the systemic metabolic state. nCritiView is the only device providing continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitochondrial function and the microcirculatory blood flow and oxygen saturation.n

I
IntelliDx

IntelliDx, Inc. is a development stage medical device company focused on the commercialization of an automated blood glucose monitoring device.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.